The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio companies
Newswires
Showing 25 of 6075
The group said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun
Harpoon is well-positioned to play a significant role in immuno-oncology, Arix said
Dr Cath O'Neill told investors: "I am determined to find a suitable individual for the CEO role with the same passion for the science, as well as commercial acumen"
The Food & Drug Administration has requested more data on the company's antibiotic
In results for the six months to 30 November 2018, the AIM-listed firm posted a pre-tax loss of £3.85mln, wider from the £2.83mln loss recorded a year earlier, although revenues rose to £121,000 from £77,000
The Phase 3 programme comprises two global, randomised, double-blind, active-controlled clinical trials which will be run concurrently with each expected to enrol around 680 patients
Faron is currently taking Clevegen through its first in-human clinical trial, and research from a university in Finland has shown that blocking a cell receptor called Clever-1 can suppress tumours
The vaccine is for Clostridium perfringens, a bacterium which normally inhabits the gastrointestinal system but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth
The Swiss Bank's analysts cut Spire's earnings per share estimates for 2018-2020 by 14-33%, while expecting the group to downgrade its underlying earnings (EBITDA) target for 2022
Sativa wants to target the “potentially lucrative” CBD veterinary market, which would see it develop cannabis-based treatments for cats, dogs and horses
The AIM-listed neuroscience data analytics company said Grant will join the company on 29 April 2019 and it is anticipated that he will join the board in due course
Following the sale of significant assets by Redag Crop Protection Ltd, the repayment criteria for a loan previously granted to Redag by Redx in October 2014 has been met
Keher has previously headed up Royal Bank of Canada’s European healthcare equity research team, while he has also held roles at GSK and Lloyd’s Pharmacy
MEDI8897 is being developed as a treatment for a respiratory syncytial virus – a major cause of lower respiratory tract infection which affects around 90% of children under two
The news comes less than a week after Midatech said Chinese billionaire, Lam Kong, would pay £8mln for a 77.3% stake in the company
Bosses expect to move another step closer towards profitability in the year ahead, before breaking even in 2020 – a long-term target for the group
Rajawali Medika will work with Collagen to obtain regulatory approval and launch ChondroMimetic in Indonesia and possibly several other South East Asian countries
The patents protect VAL301 as a treatment for endometriosis and prostate enlargement in two of the world’s most populous countries
The AIM-listed group said the decision by Deinove follows a period of nine months of evaluation during which it had sole rights to develop the Novel Bacterial Topoisomerase Inhibitor programme
The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".
ANGLE is looking to become the first company to receive FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis
The global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding in Harpoon
The AIM-listed group said its sales growth was reduced by the factors reported at the interim stage, including African Swine Flu in China and challenging trading in the Middle East and Latin America
First-quarter profits in both of UDG’s divisions – Ashfield and Sharp – were ahead of last year, and UDG expects its earnings per share to rise by around 5% in 2019
